
Health-system pharmacists confirm therapy matches stroke mechanism, screen for bleeding risk and drug interactions, and help patients transition to outpatient care.

Gillian McGovern is an editor at Pharmacy Times®. She graduated from Rowan University in 2023 with a BA in Writing Arts and concentrations in Publishing & Writing for the Public, Technical & Professional Writing, and Creative Writing.

Health-system pharmacists confirm therapy matches stroke mechanism, screen for bleeding risk and drug interactions, and help patients transition to outpatient care.

A once-nightly drop already used to reverse pupil dilation gains a near-vision indication.

Salia Farrokh describes how the role of neurocritical care pharmacists has changed over years of practice.

Salia Farrokh describes how neurocritical care pharmacists have moved from answering questions to leading research, policy, and teaching, and why health systems must fund dedicated ICU pharmacists and protected time to sustain that growth.

Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.

The panelists explain how to counsel pregnant patients with heart disease honestly without frightening them, why multidisciplinary care models matter, and how community pharmacists can help close care gaps, especially in rural areas.

Pharmacists can help identify undiagnosed interstitial lung disease (ILD) in patients with chronic obstructive pulmonary disease (COPD) whose symptoms worsen despite treatment.

No new vouchers have been awarded since former FDA Commissioner Marty Makary left the agency in May, although HHS maintains the pilot is ongoing.

The 3 panelists describe how they adjust heart failure, antihypertensive, anticoagulant, and antiarrhythmic therapy during pregnancy and after delivery, and why shared decision-making on lactation should start before delivery.

The panelists call for dedicated research, registries, and better training on medication safety in pregnancy and lactation, and describe how pharmacists can help prevent patients from stopping necessary therapy.

Two pharmacists discuss complexities patients face when starting specialty medications and predict how CVS’s restructuring and reduced specialty pharmacy lock-in may improve affordability and choice.

Marini and her 2 guests discuss why dedicated neurology pharmacy training remains scarce, why it is increasingly necessary, and how pharmacists at any career stage can enter the specialty.

Three experts say that misconceptions and fear can lead patients to stop lifesaving cardiac medications during pregnancy, and they explain how to weigh risks and benefits with reliable resources.

The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.

Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.

If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).

Erica Marini recaps October’s neurology pharmacy news, from FDA updates and new multiple sclerosis trial data to a fatal epilepsy case that shows the danger of patients relying on AI for medication advice.

Multidisciplinary institutional guidelines, more education and advocacy from pharmacists, national consensus guidance, and clinical trials that use the newer equations are needed in the hematology/oncology space.

The panelists recommend cross-comparing equations, deciding doses with the care team, and watching for patients at high risk of inaccurate estimates when moving chemotherapy dosing from Cockcroft-Gault to eGFR.

Moving from Cockcroft-Gault to race-agnostic estimated glomerular filtration rate (eGFR) for drug dosing is slowed by older trial data, inconsistent package inserts, gaps in education, and the work of updating EHR order sets.

C difficile survivor Caitlin McClain discusses the Peggy Lillis Foundation’s patient support and policy work, the need for new antibiotics and stronger stewardship, and the lasting psychological impact of the disease.

C difficile survivor Caitlin McClain describes how pharmacists helped secure her fidaxomicin supply and guide her recovery.

Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.

Caitlin McClain describes how months of unrecognized C difficile infection after antibiotic treatment led to septic shock, failed fecal transplants, and, eventually, a successful donor-directed fecal microbiota transplant.

The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.

The approval gives patients 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.

Sita Bhatt, PharmD, explains how new lung cancer therapies and oral oncology programs are expanding pharmacists’ roles in education, toxicity management, and access for underserved patients.

The PD-1 inhibitor is the first immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer and may allow eligible patients to avoid chemotherapy, radiation, and surgery.

The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.

The panel discusses when cystatin C–based eGFR equations can improve kidney function estimates for drug dosing in older adults and patients with obesity, and why clinical judgment and follow-up remain essential.